Skip to main content
Explore URMC

menu

Leukemia: A program for monitoring minimal residual disease following treatment of patients with Acute Myeloid Leukemia or High Grade Myelodysplastic Syndrome.

Research Question:
Can tests be developed to identify those patients who are at a greater risk for having their disease return?

Basic Study Information

Purpose:
This study is being performed to develop better tests to determine the impact of the therapy you are receiving for treatment of your AML or MDS and to determine if these tests can identify those patients who are at a greater risk for having their disease relapse. Following therapy, the majority of patients with AML and many patients with MDS will achieve a remission that is defined by the lack of any evidence of the disease when viewing bone marrow samples under a microscope. Despite the absence of disease by this method, many patients in remission will still have what is referred to as Minimal Residual Disease when more sensitive methods are applied. That is, even though the disease cannot be seen by routine staining under the microscope, more sensitive tests can detect its presence. The presence of Minimal Residual Disease following therapy does not guarantee that the patient will experience a relapse. This is likely a result of the failure of these techniques to examine those cells that are responsible for disease relapse. Recent data suggests that in the majority of patients with AML or MDS only a minor population of the malignant cells are capable of maintaining the disease and are likely responsible for relapse following therapy. This minor population of cells can be identified by the proteins they have on their surface. This study tests the ability to identify Minimal Residual Disease following therapy by performing special assays that specifically target this minor population of malignant cells.

Location: Cancer Center
Study Reference #: ULEU-07047

Lead Researcher (Principal Investigator)

Lead Researcher: Michael Becker, MD

Study Contact Information

Study Coordinator: Brandon DeLorme
Phone: (585) 275-5295
Email: Brandon_Delorme@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Leukemia

More information about Leukemia, Myeloid

More information about Leukemia, Myeloid, Acute

More information about Myeloid leukemia

More information about Myeloid leukemia, acute

Return to Search